Tranexamic Acid During Colonic Endoscopic Resection Procedures
ConditionColon Neoplasm
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssaf-Harofeh Medical Center
About this trial
Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
Eligibility criteria
Qualifiers
Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
Age > 18 years
Disqualifiers
patients with histories of allergic reactions to TXA
history of seizures
pregnancy
Trial design
Treatments tested in this trial
- Tranexamic acid
- Standard
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov